Objective To evaluate the efficacy of specific immunotherapy in combination with budesonide formoterol dry powder inhaler ( BUD/FM) in the treatment of moderate to severe bronchial asthma. Methods The data of 93 patients with moderate to severe asthma from September 2006 to September 2008 were analyzed. 46 cases who received BUD/FM therapy were recorded as a BUD/FM treatment group, and 47 cases who received BUD/FMand dustmite specific immunotherapy were recorded as
a combination treatment group. After 6, 12, 18, and 24 months, asthma symptom scores, pulmonary function,effective rate, and scores of Asthma Quality of Life Questionnaire ( AQLQ) were compared in the two treatment groups. Results Compared with the BUD/FMtreatment group, the effective rate was significantly
higher ( 83. 0% vs. 65. 2% , P lt;0. 05) , the lung function improvements in FEV1% pred and expiratory peak flow were more significant in the latter period of treatment, and AQLQ scores improved more significantly after 24 months’treatment in the combination treatment group. Conclusion For patients with moderate to
severe asthma, specific immunotherapy in combination with BUD/FMcan improve asthma symptoms and lung function with good compliance and long lasting efficacy.
Citation：
LI Hongyan,XIAO Xinrong,YE Xingrong,HU Yongxia,WANGWei.. Efficacy of Specific Immunotherapy Combined with Budesonide Formoterol Dry Powder Inhaler for Treatment of Moderate to Severe Asthma. Chinese Journal of Respiratory and Critical Care Medicine, 2010, 9(4): 374-377. doi:
Copy
Copyright © the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
| 1. |
汤葳. 支气管哮喘的特异性免疫治疗新进展. 国外医学呼吸系统分册, 2001, 21 : 149-150.
|
| 2. |
中华医学会呼吸病学会哮喘学组. 支气管哮喘防治指南( 支气管哮喘的定义、诊断、治疗及教育和管理方案) . 中华内科杂志,2003, 42: 817-822 .
|
| 3. |
李善群, 钮善福, 姜丽岩, 等. 扎鲁司特片治疗113 例支气管哮喘的临床应用. 临床肺科杂志, 2002, 7: 4 -5.
|
| 4. |
Juniper EF, Guyatt GH, Ferrie PJ, et al . Measuring quality of life in asthma. Am Rev Respir Dis, 1993, 147: 832-838.
|
| 5. |
中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南( 支气管哮喘的定义、诊断、治疗及教育和管理方案) . 中华结核和呼吸杂志, 1997, 20: 261-263.
|
| 6. |
李明华. 哮喘病的脱敏治疗. 中国临床医生, 2004, 32: 12-13.
|
| 7. |
刘春涛, 王曾礼, 主编. 气道炎症性疾病. 北京: 人民卫生出版社, 2004, 4-7 .
|
| 8. |
沈华浩, 吴祖群. 哮喘变应原特异性免疫治疗的若干问题. 中国呼吸与危重监护杂志. 2006, 5: 91-93.
|
| 9. |
刘春涛. 中重度哮喘治疗方案的调整. 中国呼吸与危重监护杂志, 2007, 6: 329 -331.
|
| 10. |
Bateman ED, Bantje TA, Joao Gomes M, et al. Combination therapy with single inhaler budesonide/ formaterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med, 2003 , 2: 275-281 .
|
| 11. |
Abramson M, Puy R, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev, 2003, ( 4) : CD001186.
|
- 1. 汤葳. 支气管哮喘的特异性免疫治疗新进展. 国外医学呼吸系统分册, 2001, 21 : 149-150.
- 2. 中华医学会呼吸病学会哮喘学组. 支气管哮喘防治指南( 支气管哮喘的定义、诊断、治疗及教育和管理方案) . 中华内科杂志,2003, 42: 817-822 .
- 3. 李善群, 钮善福, 姜丽岩, 等. 扎鲁司特片治疗113 例支气管哮喘的临床应用. 临床肺科杂志, 2002, 7: 4 -5.
- 4. Juniper EF, Guyatt GH, Ferrie PJ, et al . Measuring quality of life in asthma. Am Rev Respir Dis, 1993, 147: 832-838.
- 5. 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南( 支气管哮喘的定义、诊断、治疗及教育和管理方案) . 中华结核和呼吸杂志, 1997, 20: 261-263.
- 6. 李明华. 哮喘病的脱敏治疗. 中国临床医生, 2004, 32: 12-13.
- 7. 刘春涛, 王曾礼, 主编. 气道炎症性疾病. 北京: 人民卫生出版社, 2004, 4-7 .
- 8. 沈华浩, 吴祖群. 哮喘变应原特异性免疫治疗的若干问题. 中国呼吸与危重监护杂志. 2006, 5: 91-93.
- 9. 刘春涛. 中重度哮喘治疗方案的调整. 中国呼吸与危重监护杂志, 2007, 6: 329 -331.
- 10. Bateman ED, Bantje TA, Joao Gomes M, et al. Combination therapy with single inhaler budesonide/ formaterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med, 2003 , 2: 275-281 .
- 11. Abramson M, Puy R, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev, 2003, ( 4) : CD001186.
